QIAGEN has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio for gastrointestinal infections. The panel rapidly detects five key bacterial pathogens—Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica—in about one hour, supporting fast outpatient diagnostics. This is QIAGEN’s second FDA-cleared QIAstat-Dx panel in 2025 and complements their existing bacterial and viral GI panels, offering laboratories targeted, flexible solutions for diverse clinical settings.
Trending
- Cancer risk comparable across advanced IBD therapies in claims analysis (GI & Hepatology News)
- Independent practice on the road to extinction: Why the next generation won’t own the stethoscope, let alone the building (Medical Economics)
- Fecal Burden on CT Weakly Correlates with Bowel Function in Adults and is Poorly Associated with Clinical Symptoms (Digestive Diseases and Sciences)
- Cook Medical issues medical device correction for Hemospray Endoscopic Hemostat (AGA)
- Medicare physician pay reform 2027: Patients First Act and 4 other bills explained (Physicians Practice)
- FDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test (PR Newswire)
- Batteries that safely break down in the GI tract could improve ingestible devices (Medical Xpress)
- Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls (Gastroenterology)
